Treatment of hepatic metastases from colorectal cancer: Many doubts, some certainties

Cancer Treatment Reviews

Volumn 32, Issue 3, 2006, Pages 214-228

  Biasco, G ^a   Derenzini, E ^a   Grazi, GL ^a   Ercolani, G ^a   Ravaioli, M ^a   Pantaleo, M A ^a   Brandi, G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

5 fluorouracil; Colorectal cancer; Hepatectomy; Irinotecan; Liver metastases; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

CANCER MORTALITY; CANCER SURVIVAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CRYOSURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; INTERMETHOD COMPARISON; LIFE EXPECTANCY; LIVER METASTASIS; LIVER RESECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PROBABILITY; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CRYOSURGERY; DECISION TREES; FLUOROURACIL; HEPATECTOMY; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33646092271     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.12.011     Document Type: Review

References (104)

1. In: Sabin L.H., and Wittekind Ch. (Eds). UICC TNM classification of malignant tumours. 6th ed. (2002), Wiley, New York
2. Penna C., and Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin N Am 82 (2002) 1075-1090
3. Stangl R., Altendorf-Hofmann A., Charnley R.M., and Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 343 (1994) 1405-1410
4. Wanebo H.J., Semoglou C., Attiyeh F., and Stearns Jr. M.J. Surgical management of patients with primary operable colorectal cancer and synchronous liver metastases. Am J Surg 135 (1978) 81-85
5. Pichlmayr R. Is there a place for liver grafting for malignancy?. Transpl Proc 20 (1988) 478-482
6. Wray C.J., Lowy A.M., Mathews J.B., et al. The significance and clinical factors associated with a subcentimeter resection of colorectal liver metastases. Ann Surg Oncol 12 5 (2005) 374-380
7. Cady B., Jenkins R.L., Steele Jr. G.D., et al. Surgical margin in hepatic resection for colorectal metastasis. Ann Surg 227 (1998) 566-571
8. Kokudo N., Miki Y., Sugai S., et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 137 7 (2002) 833-840
9. Nordlinger B., Guiguet M., Vaillant J.C., et al. Surgical resection of colorectal carcinoma to the liver. Cancer 77 (1996) 1254-1262
10. Fong Y., Fortner J., Sun R.L., Brennan M.F., and Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230 3 (1999) 309-318 discussion 318-321
11. Scheele J., Stangl R., Altendorf-Hofmann A., and Gall F.P. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 110 (1991) 13-29
12. Ercolani G., Grazi G.L., Ravaioli M., et al. Liver resection for multiple colorectal metastases: Influence of parenchymal involment and total tumor volume, vs. number or location, on long-term survival. Arch Surg 137 (2002) 1187-1192
13. Minagawa M., Makuuchi M., Torzilli G., et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 231 4 (2000) 487-499
14. Kokudo N., Sato T., Seki M., et al. Hepatic lymph node involvement in resected cases of liver metastases from colorectal cancer. Dis Colon Rectum 42 (1999) 1285-1291
15. Nagashima I., Takada T., Matsuda K., et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg 11 (2004) 79-83
16. Ercolani G., Grazi G.L., Ravaioli M., et al. The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann Surg Oncol 12 (2005) 459-466
17. Valls C., Andia E., Sanchez A., et al. Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. Radiology 218 1 (2001) 55-60
18. Kinkel K., Lu Y., Both M., Warren R.S., and Thoeni R.F. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 224 3 (2002) 748-756
19. Quaia E., Bertolotto M., Forgacs B., Rimondini A., Locatelli M., and Mucelli R.P. Detection of liver metastases by pulse inversion harmonic imaging during Levovist late phase: comparison with conventional ultrasound and helical CT in 160 patients. Eur Radiol 13 3 (2003) 475-483
20. Ward J., Robinson P.J., Guthrie J.A., et al. Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology 237 1 (2005) 170-180
21. Mann G.N., Marx H.F., Lai L.L., and Wagmann L.D. Clinical and cost effectiveness of a new hepatocellular MRI contrast agent, mangafodipir trisodium, in the preoperative assessment of liver resectability. Ann Surg Oncol 8 7 (2001) 573-579
22. Strasberg S.M., Dehdashti F., Siegel B.A., Drebin J.A., and Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 233 3 (2001) 293-299
23. Staren E.D., Gambla M., Deziel D.J., et al. Intraoperative ultrasound in the management of liver neoplasms. Am Surg 63 7 (1997) 591-596 discussion 596-597
24. Clouse M.E. Current dagnostic imaging modalities of the liver. Surg Clinics N Am 69 2 (1989) 193-234
25. Peppercorn P.D., Reznek R.H., Wilson P., Slevin M.L., and Gupta R.K. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 77 11 (1998) 2008-2011
26. Elias D., Youssef O., Dromain C., et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 86 (2004) 4-9
27. Elias D., Sideris L., Pocard M., et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 11 3 (2004) 274-280
28. Headrick J.R., Miller D.L., Nagorney D.M., et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 71 (2001) 975-979 discussion 979-980
29. Regnard J.F., Grunenwald D., Spaggiari L., et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 66 (1998) 214-218 discussion 218-219
30. Pastorino U. Lung metastasectomy for colorectal cancer. Tumori 83 Suppl. 1 (1997) S28-S29
31. Saito Y., Omiya H., Kohno K., et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. J Thorac Cardiovasc Surg 124 (2002) 1007-1013
32. Okumura S., Kondo H., Tsuboi M., et al. Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 112 4 (1996) 867-874
33. Masayoshi I., Kotake Y., Nakagawa K., Fujiwara K., Fukuhara K., and Yasumitsu T. Surgery for pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 70 (2000) 380-383
34. Wein A., Riedel C., Bruckl W., et al. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 64 (2003) 131-138
35. Allen P.J., Kemeny N., Jarnagin W., DeMatteo R., Blumgart L., and Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 7 1 (2003) 109-115
36. Adam R., Pascal G., Casing D., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg 240 6 (2004) 1052-1061
37. Adam R., Laurent A., Azoulay D., Castaing D., and Bismuth H. Two stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 232 (2000) 777-785
38. Meta-Analysis group in cancer. Reappraisal of hepatic arterial infusion in the treatment of non resectable liver metastases from colorectal cancer. J Natl Cancer Inst 88 (1996) 252-258
39. Kerr D.J., McArdle C.S., Ledermann J., et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 361 9355 (2003) 368-373
40. De Gramont A., Bosset J.F., Milan C., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15 2 (1997) 808-815
41. Van Cutsem E., Hoff P.M., Harper P., et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90 6 (2004) 1190-1197 March 22
42. De Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 16 (2000) 2938-2947
43. Levi F., Zidani R., and Misset J.L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350 9079 (1997) 681-686 September 6
44. Cassidy J., Tabernero J., Twelves C., et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22 11 (2004) 2084-2091 June 1
45. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
46. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 2 (2004) 229-237 January 15
47. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 9209 (2000) 1041-1047 March 25
48. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 13 (2000) 905-914 September 28
49. Bajetta E., Di Bartolomeo M., Mariani L., et al. Italian Trials in Medical Oncology (I.T.M.O.) Group. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100 2 (2004) 279-287 January 15
50. Falcone A., Masi G., Allegrini G., et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 20 19 (2002) 4006-4014 October 1
51. Souglakos J., Mavroudis D., Kakolyris S., et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol 20 11 (2002) 2651-2657 June 1
52. Abad A., Antón A., Massuti B., et al. Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRC) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU. Final results of a Phase II study. Proc Am Soc Clin Oncol 23 (2005) 275 Abstract 3618
53. Hurwitz H., Ferhenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl Med 350 23 (2004) 2335-2342 June 3
54. Kabbinavar F., Schultz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23 (2005) 3697-3705
55. Bismuth H., Adam R., Levi F., et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224 4 (1996) 509-520 discussion 520-522
56. Wein A., Riedel C., Kockering F., et al. Impact of surgery in palliative patients with metastatic colorectal cancer after first line-treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol 12 (2001) 1721-1727
57. Giacchetti S., Itzhaki M., Gruia G., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10 6 (1999) 663-669
58. Pozzo C., Basso M., Cassano A., et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and fluorouracil plus folinic acid in colorectal cancer liver metastases. Ann Oncol 15 6 (2004) 933-939
59. Masi G., Allegrini G., Cupini S., et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 15 12 (2004) 1766-1772
60. Falcone A., Masi G., Cupini S., et al. Surgical resection of metastases (mts) after biweekly chemotherapy with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI) in initially unresectable metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 23 (2004) 258 Abstract 3553
61. Kemeny N., Gonen M., Sullivan D., et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 19 10 (2001) 2687-2695 May 15
62. Leonard G., Fong D., Jarnagin R., et al. Liver resection after hepatic arterial infusion plus systemic oxaliplatin (Oxal) combinations in pretreated patients with extensive unresectable colorectal liver metastases. Proc Am Soc Clin Oncol 23 (2004) 256 Abstract 3542
63. Janinis J., Papakostas P., Samelis G., Skarlos D., Papagianopoulos P., and Fountzilas G. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Ann Oncol 11 2 (2000) 163-167
64. Kouroussis C., Souglakos J., Mavroudis D., et al. Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). Am J Clin Oncol 25 6 (2002) 627-631
65. Ryan D.P., Clark J.W., Kulke M.H., et al. A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. Cancer Invest 21 4 (2003) 505-511
66. Rothenberg M.L., Oza A.M., Bigelow R.H., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21 11 (2003) 2059-2069 June 1
67. Giantonio B.J., Catalano P.J., Meropol N.J., et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol 23 (2005) 1 Abstract 2
68. Andre T., Louvet C., Maindrault-Goebel F., et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35 9 (1999) 1343-1347
69. Ulrich-Pur H., Kornek G.V., Fiebiger W., et al. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Ann Oncol 12 9 (2001) 1269-1272
70. Stickel F., Jungert B., Brueckl V., et al. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin. Anticancer Drugs 14 9 (2003) 745-749
71. Tai C.J., Liu J.H., Chen W.S., et al. Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan. Jpn J Clin Oncol 33 3 (2003) 136-140
72. Mabro M., Louvet C., Andre T., et al. Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol 26 3 (2003) 254-258
73. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
74. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
75. Folprecht G., Grothey A., Alberts S., Raab H.R., and Kohne C.H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16 8 (2005) 1311-1319
76. Tebbut N.C., Norman A.R., Cunningham D., et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 52 (2003) 568-573
77. Scoggins C.R., Meszoely I.M., Blanke C.D., Beauchamp R.D., and Leach S.D. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 6 7 (1999) 651-657
78. Brandi G., Pantaleo M.A., Calabrese C., et al. Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine. Int J Colorectal Dis 19 6 (2004) 599-602
79. Scartozzi M., Bearzi I., Berardi R., Mandolesi A., Fabris G., and Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22 23 (2004) 4772-4778
80. Nash G.M., Saltz L.B., Kemeny N.E., et al. Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Ann Surg Oncol 9 10 (2002) 954-960
81. Krook J.E., Moertel C.G., Gunderson L.L., et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324 (1991) 709-715
82. O'Connel M.J., Martenson J.A., Wieand H.S., et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331 (1994) 502-507
83. Smalley S.R., Benedetti J., Williamson S., et al. Intergroup 0144-phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs. prolonged venous infusion (PVI) before and after XRT + PVI vs. bolus 5-FU + Leucovorin (LV) + Levamisole (LEV) before and after XRT + bolus 5-FU + LV. Proc Am Soc Clin Oncol 22 (2003) 251 Abstract 1006
84. Fernandez F.G., Goodwin J.W., Linehan D.C., Hawkins W.G., and Strasberg S.M. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200 6 (2005) 845-853
85. Ekberg H., Tranberg K.G., Andersson R., et al. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 11 (1987) 541-547
86. Petrowsky H., Gonen M., Jarnagin W., et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer. Ann Surg 235 (2002) 863-871
87. Adam R., Pascal G., Azoulay D., Tanaka K., Castaing D., and Bismuth H. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 238 (2003) 871-883 discussion 883-884
88. Scheele J., Stangl R., and Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77 (1990) 1241-1246
89. Pearson A.S., Izzo F., Fleming D., et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 178 (1999) 592-599
90. Bilchik A.J., Wood T.F., Allegra D., et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg 135 6 (2000) 657-662
91. Adam R., Hagopian E., Linhares M., et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg 137 (2002) 1332-1339
92. Bleicher R., Allegra D., Nora D., Wood T.F., Foshag L.J., and Bilchik A.J. Radiofrequency ablation in 447 complex unresectable liver tumors: lesson learned. Arch Surg Oncol 10 (2003) 52-58
93. Solbiati L., Livraghi T., Goldberg S., et al. Percutaneous radiofrequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221 (2001) 159-166
94. Berber E., Pelley R., and Siperstein A. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver. J Clin Oncol 23 (2005) 1358-1364
95. Abdalla E.K., Vauthey J.N., Ellis L.M., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239 6 (2004) 818-825
96. Oshowo A., Gillams A., Harrison E., Lees W.R., and Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary collorectal liver metastases. Br J Surg 90 (2003) 1240-1243
97. Livraghi T., Solbiati L., Meloni F., Ierace T., Goldberg S.N., and Gazelle G.S. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the "test-of-time approach. Cancer 97 12 (2003) 3027-3035
98. Poston G.J. Radiofrequency ablation of colorectal liver metastases: Where are we really going?. J Clin Oncol 23 (2005) 1342-1344
99. Lorenz M., Muller H.H., Schramm H., et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 228 (1998) 756-762
100. Kemeny N., Huang Y., Cohen A.M., et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341 (1999) 2039-2048
101. Kemeny M.M., Adak S., Gray B., et al. Combined modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - An intergroup study. J Clin Oncol 20 (2002) 1499-1505
102. Figueras J., Valls C., Rafecas A., Fabregat J., Ramos E., and Jaurrieta E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 88 (2001) 980-985
103. Brandi G, Derenzini E, Pantaleo MA, et al. Systemic adjuvant chemotherapy after resection of colorectal cancer metastases. In: Sixth National Congress of Medical Oncology, 21-24 September, 2004, Bologna, Italy, Session of Oral Communications on Colorectal Cancer, September 23, 2004, Abstract E38.
104. Nordlinger B, Sorbye H, Debois M, et al. Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983. In: Proceedings of the American Society for Clinical Oncology, 2005, Abstract 3528.